These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 11586419)

  • 1. New experimental model of multiple myeloma.
    Telegin GB; Kalinina AR; Ponomarenko NA; Ovsepyan AA; Smirnov SV; Tsybenko VV; Homeriki SG
    Bull Exp Biol Med; 2001 Jun; 131(6):609-12. PubMed ID: 11586419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Experimental animal models of multiple myeloma].
    Miyakawa Y
    Nihon Rinsho; 2007 Dec; 65(12):2211-7. PubMed ID: 18069262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Establishment of a multiple myeloma local tumor model in mice].
    Liu Y; Zhou MY; Meng WT; Xu CG
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Jun; 18(3):647-51. PubMed ID: 20561420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Animal model of human disease. Multiple myeloma.
    Radl J; Croese JW; Zurcher C; Van den Enden-Vieveen MH; de Leeuw AM
    Am J Pathol; 1988 Sep; 132(3):593-7. PubMed ID: 3414786
    [No Abstract]   [Full Text] [Related]  

  • 5. In vivo efficacy of the diuretic agent ethacrynic acid against multiple myeloma.
    Kim Y; Gast SM; Endo T; Lu D; Carson D; Schmidt-Wolf IG
    Leuk Res; 2012 May; 36(5):598-600. PubMed ID: 22386728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A bioluminescence imaging based in vivo model for preclinical testing of novel cellular immunotherapy strategies to improve the graft-versus-myeloma effect.
    Rozemuller H; van der Spek E; Bogers-Boer LH; Zwart MC; Verweij V; Emmelot M; Groen RW; Spaapen R; Bloem AC; Lokhorst HM; Mutis T; Martens AC
    Haematologica; 2008 Jul; 93(7):1049-57. PubMed ID: 18492693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody-based delivery of tumor necrosis factor (L19-TNFα) and interleukin-2 (L19-IL2) to tumor-associated blood vessels has potent immunological and anticancer activity in the syngeneic J558L BALB/c myeloma model.
    Menssen HD; Harnack U; Erben U; Neri D; Hirsch B; Dürkop H
    J Cancer Res Clin Oncol; 2018 Mar; 144(3):499-507. PubMed ID: 29327244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [MUC1-2VNTR DNA Vaccine Induces Immune Responses in Mouse Model with Multiple Myeloma].
    Liu YB; Zhou ZP; Wang H; Yang H; Mu H; Huang GY; Zhang Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Oct; 23(5):1366-9. PubMed ID: 26524039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erythropoietin has an anti-myeloma effect - a hypothesis based on a clinical observation supported by animal studies.
    Mittelman M; Zeidman A; Kanter P; Katz O; Oster H; Rund D; Neumann D
    Eur J Haematol; 2004 Mar; 72(3):155-65. PubMed ID: 14962233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of animal models in multiple myeloma.
    Libouban H
    Morphologie; 2015 Jun; 99(325):63-72. PubMed ID: 25898798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models.
    Mittelman M; Neumann D; Peled A; Kanter P; Haran-Ghera N
    Proc Natl Acad Sci U S A; 2001 Apr; 98(9):5181-6. PubMed ID: 11309490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe combined immunodeficiency (SCID) mouse modeling of P-glycoprotein chemosensitization in multidrug-resistant human myeloma xenografts.
    Bellamy WT; Odeleye A; Huizenga E; Dalton WS; Weinstein RS; Grogan TM
    Clin Cancer Res; 1995 Dec; 1(12):1563-70. PubMed ID: 9815957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experimental plasmacytomas in relation to human multiple myeloma.
    Azar HA
    Ann Clin Lab Sci; 1974; 4(3):157-63. PubMed ID: 4825619
    [No Abstract]   [Full Text] [Related]  

  • 14. beta-catenin small interfering RNA successfully suppressed progression of multiple myeloma in a mouse model.
    Ashihara E; Kawata E; Nakagawa Y; Shimazaski C; Kuroda J; Taniguchi K; Uchiyama H; Tanaka R; Yokota A; Takeuchi M; Kamitsuji Y; Inaba T; Taniwaki M; Kimura S; Maekawa T
    Clin Cancer Res; 2009 Apr; 15(8):2731-8. PubMed ID: 19351774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse effects of mouse hepatitis virus on ascites myeloma passage in the BALB/eJ mouse.
    Fox JG; Murphy JC; Igras VE
    Lab Anim Sci; 1977 Apr; 27(2):173-9. PubMed ID: 192942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sialic acid content in mouse myeloma cells and derived B-cell hybridomas with different metastatic potentials.
    Friedman J; Levinsky H; Allalouf D; Staroselsky A
    Cancer Lett; 1988 Dec; 43(1-2):79-84. PubMed ID: 3264519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A mouse model for immunotherapy of myeloma.
    Bogen B
    Hematol J; 2002; 3(5):224-9. PubMed ID: 12391539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transfer of idiotypic protein primed allogeneic marrow grafts elicits potent graft-versus-myeloma effects in mice.
    Zeis M; Steinmann J; Petrela E; Hartung G; Schmitz N; Uharek L
    Bone Marrow Transplant; 2001 Feb; 27(3):279-85. PubMed ID: 11277175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of the differentially expressed genes in SP2/0 myeloma cells from Balb/c mice infected with Trichinella spiralis.
    Deng B; Gong P; Li J; Cheng B; Ren W; Yang J; Li H; Zhang G; Zhang X
    Vet Parasitol; 2013 May; 194(2-4):179-82. PubMed ID: 23473833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic antitumor efficacy of anti-CD137 agonistic monoclonal antibody in mouse models of myeloma.
    Murillo O; Arina A; Hervas-Stubbs S; Gupta A; McCluskey B; Dubrot J; Palazón A; Azpilikueta A; Ochoa MC; Alfaro C; Solano S; Pérez-Gracia JL; Oyajobi BO; Melero I
    Clin Cancer Res; 2008 Nov; 14(21):6895-906. PubMed ID: 18980984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.